| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| topiramate | carbonic anhydrase 1 | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.16 | approved | inhibitor |
| topiramate | carbonic anhydrase 2 | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.51 | approved | inhibitor |
| topiramate | carbonic anhydrase 3 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
NA | approved | inhibitor |
| topiramate | carbonic anhydrase 4 | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.79 | approved | inhibitor |
| topiramate | voltage gated l-type calcium channel | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
NA | approved | antagonist |
| topiramate | voltage gated l-type calcium channel | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
NA | approved | antagonist |
| topiramate | voltage-dependent r-type calcium channel | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
NA | approved | antagonist |
| topiramate | voltage gated l-type calcium channel | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
NA | approved | antagonist |
| topiramate | voltage gated l-type calcium channel | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
NA | approved | antagonist |
| topiramate | voltage gated l-type calcium channel | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
NA | approved | antagonist |
| topiramate | voltage gated l-type calcium channel | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
NA | approved | antagonist |
| topiramate | voltage gated l-type calcium channel | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
NA | approved | antagonist |
| topiramate | voltage gated l-type calcium channel | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
NA | approved | antagonist |
| topiramate | gamma-aminobutyric acid receptor subunit alpha-1 | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.14 | approved | agonist |
| topiramate | kainate receptors | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
3.26 | approved | antagonist |
| topiramate | glutamate receptor ionotropic kainate 1 | NA | Successful target | TTD , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
3.26 | approved | unknown |
| topiramate | glutamate receptor ionotropic kainate 1 | NA | Successful target | TTD , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
3.26 | approved | antagonist |
| topiramate | kainate receptors | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.1 | approved | antagonist |
| topiramate | kainate receptors | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.37 | approved | antagonist |
| topiramate | kainate receptors | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.3 | approved | antagonist |
| topiramate | kainate receptors | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
NA | approved | antagonist |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.02 | approved | inhibitor,blocker |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.02 | approved | inhibitor,blocker |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.19 | approved | inhibitor |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.19 | approved | inhibitor,blocker |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.1 | approved | inhibitor |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.1 | approved | inhibitor,blocker |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.02 | approved | inhibitor,blocker |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.02 | approved | inhibitor,blocker |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.02 | approved | inhibitor,blocker |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.03 | approved | inhibitor,blocker |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.03 | approved | inhibitor,blocker |
| topiramate | voltage-gated sodium channel alpha subunit | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Disease[MeSHID:D004194] Body Weight[MeSHID:D001835] Lennox-Gastaut syndrome[MeSHID:D065768] Mood Disorders[MeSHID:D019964] Off-Label Use[MeSHID:D056687] Seizures Focal[MeSHID:D012640] Migraine Disorders[MeSHID:D008881] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Alcoholic Intoxication Chronic[MeSHID:D000437] Epilepsy[MeSHID:D004827] |
0.02 | approved | inhibitor,blocker |
| click here to return to the previous page | ||||||||